Market gap Target urgent cell and viral vector therapy manufacturers and contract development organizations with CBio’s rapid contamination detection and empty particle identification to shorten release timelines and reduce weeks of testing, addressing a clear bottleneck in biomanufacturing quality control.

Quality edge Position CBio as a provider of high-speed, edge-accelerated testing solutions that integrate with existing QC workflows, offering faster quality assurance and safer patient release for gene therapies.

Tech enablement Leverage CBio’s novel separation science, machine vision, and cloud/edge computing capabilities to upsell instrumentation, kits, and scalable testing platforms to biopharma labs seeking automation and real-time monitoring.

Strategic partnerships Pursue collaborations with early-stage and CROs focusing on gene therapies to co-develop standardized testing regimes, enabling faster validation, regulatory readiness, and broader market adoption.

Funding signals Highlight the company’s lean funding profile and growth potential to attract pilots or grant-backed trials, offering low-risk entry points for labs needing accelerated quality testing and demonstration projects.